On May 5, 2024, Johnson & Johnson Updated Results From Multi-Cohort Phase 1 Study Of The Safety And Efficacy; TAR-210 Results Show 90% Recurrence-Free Survival And 90% Complete Response In Patients With High-Risk And Intermediate-Risk Non-Muscle-Invasive Bladder Cancer, Respectively
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson announced updated results from a Phase 1 study of TAR-210, showing 90% recurrence-free survival in high-risk NMIBC patients and 90% complete response in intermediate-risk patients. The study highlights TAR-210's potential as a bladder-sparing, BCG-free treatment for bladder cancer with FGFR alterations. The results were presented at the 2024 AUA Annual Meeting. TAR-210 is an investigational system delivering sustained erdafitinib release, previously approved by the FDA for certain urothelial carcinomas.
May 06, 2024 | 2:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's TAR-210 demonstrates significant efficacy in treating non-muscle-invasive bladder cancer, with high rates of recurrence-free survival and complete response.
The positive results from the Phase 1 study of TAR-210 not only highlight its potential as a transformative treatment for bladder cancer but also reinforce Johnson & Johnson's position in oncology research. Given the high efficacy rates and the drug's potential to offer a bladder-sparing, BCG-free treatment option, this development could positively impact JNJ's stock in the short term by enhancing its portfolio and demonstrating its commitment to addressing unmet medical needs.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90